Sign up to save your data!
Some tips to help get started:
Processing...
There are 382 active trials for advanced/metastatic non-small cell lung cancer. Click on a trial to see more information.
382 trials meet filter criteria.
Sort by:
HealthScout AI summary: This trial targets adult patients with advanced solid tumors, including NSCLC, melanoma, liposarcoma, leiomyosarcoma, and SCCHN, who have exhausted standard treatments. It evaluates OR2805, a monoclonal antibody targeting CD163 to modulate tumor-associated macrophages, administered alone or with cemiplimab or docetaxel.
ClinicalTrials.gov ID: NCT05094804
HealthScout AI summary: This trial assesses BT8009, a Bicycle Toxin Conjugate targeting Nectin-4, both as monotherapy and combined with pembrolizumab, in patients with advanced Nectin-4 expressing solid tumors such as urothelial carcinoma, breast, NSCLC, and ovarian cancers, who have progressed after prior treatment or lack standard therapy options. The study evaluates safety, pharmacokinetics, and preliminary efficacy, with previously reported promising response rates in treated urothelial cancer patients.
ClinicalTrials.gov ID: NCT04561362
HealthScout AI summary: The trial investigates the use of AG01, an anti-progranulin/GP88 monoclonal antibody, in patients with relapsed or refractory advanced solid tumors, including triple negative breast cancer, hormone-resistant breast cancer, non-small cell lung cancer, and mesothelioma, who have no remaining effective treatment options. AG01 is administered biweekly to evaluate its safety, tolerability, and preliminary anti-tumor activity.
ClinicalTrials.gov ID: NCT05627960
HealthScout AI summary: This trial is focused on patients with metastatic or locally advanced solid tumors, specifically colorectal cancer and non-small cell lung cancer, investigating the safety and efficacy of EU101, an agonistic monoclonal antibody targeting the 4-1BB receptor to enhance immune response.
ClinicalTrials.gov ID: NCT04903873
HealthScout AI summary: This trial targets patients with locally advanced or metastatic solid tumors, such as melanoma, non-small cell lung cancer, and triple-negative breast cancer, who have exhausted standard treatments, evaluating the safety and efficacy of DF6002, a monovalent IL-12 Fc fusion protein, both as a monotherapy and in combination with the PD-1 inhibitor Nivolumab. Eligible participants must have an ECOG performance status of 0 or 1 and adequate organ function.
ClinicalTrials.gov ID: NCT04423029
HealthScout AI summary: This trial involves patients with refractory or relapsed locally advanced or metastatic solid tumors, such as HNSCC, NSCLC, and ccRCC, evaluating the investigational drug ABBV-CLS-484, an orally bioavailable inhibitor of PTPN2 and PTPN1 that enhances immune responses, as monotherapy or in combination with PD-1 inhibitors or VEGFR TKIs.
ClinicalTrials.gov ID: NCT04777994
HealthScout AI summary: The trial involves patients with advanced solid tumors characterized by RET gene abnormalities, where TAS0953/HM06, a selective RET inhibitor targeting the RET receptor tyrosine kinase, is administered to evaluate safety, dosing, and treatment efficacy. Phase II specifically includes NSCLC patients with RET gene fusion, assessing both those previously treated with RET inhibitors and those who have exhausted existing therapies.
ClinicalTrials.gov ID: NCT04683250
HealthScout AI summary: This trial enrolls adult patients with chemo-resistant non-small cell lung cancer, head and neck squamous cell carcinoma, cervical, and uterine cancers, who express the NEO-201 antigen, to evaluate the combination of NEO-201, a monoclonal antibody targeting specific cancer cell glycans, with pembrolizumab, to potentially overcome resistance to checkpoint inhibitors.
ClinicalTrials.gov ID: NCT03476681
HealthScout AI summary: This trial targets adult patients with advanced or metastatic solid tumors having RAS, NF1, or RAF mutations, evaluating DCC-3116, an oral ULK1/2 inhibitor that blocks autophagy, both as monotherapy and in combination with trametinib, binimetinib, or sotorasib.
ClinicalTrials.gov ID: NCT04892017
HealthScout AI summary: This trial involves adult patients with advanced or metastatic solid tumors such as melanoma and non-small cell lung cancer who have relapsed after standard treatments, testing the investigational agent ST-067 alone or with pembrolizumab and obinutuzumab to enhance immune response against tumor cells.
ClinicalTrials.gov ID: NCT04787042
